Funding profile · Consumer brain imaging

BrainKey

Seven years of operation, no Regulation D filing of any kind, and four data providers who cannot agree on how much money went in. This page sets out what the public record supports.

Data as of September 23, 2026. Vendor-reported and company-reported figures are labeled. No figure here comes from a securities filing, because there is none.

Rounds at a glance

What the public record shows

Reading the record

1. No Form D does not mean no money.Regulation D is one exemption among several. Securities placed under Section 4(a)(2), and many accelerator-era convertible instruments, trigger no notice. The absence proves only that BrainKey never ran an offering that required the form, which at this reported size is unremarkable rather than suspicious.
2. The providers disagree by more than a factor of two.CB Insights: “Brain Key has raised $150K over 4 rounds.” Tracxn: “Brainkey has raised a total of $150K from 1 Seed round on Mar 19, 2019 from Y Combinator.” PitchBook: “Brainkey has raised $350K.” Dealroom itemises a $200k seed and a $125k seed, which is $325k, plus a spinout and a convertible with no figures. The $200K gap between the low and high totals is larger than any single disclosed round.
3. The investor counts disagree too.CB Insights counts 7, Tracxn counts 8, PitchBook counts 13. Taking each provider on its own terms, $150,000 across 7 investors averages about $21,400 each, and $350,000 across 13 averages about $26,900 each. Both figures are angel scale. Neither is consistent with an institutional priced round.
4. The last dated round is seven years old.Every provider places the last precisely dated financing in 2019, with PitchBook alone adding an early stage entry in December 2021. The company has operated continuously since, at a headcount reported as 20 by Y Combinator and 14 by PitchBook.
5. The capital does not match the regulatory neighbourhood.The three named comparators in brain volumetry hold twelve FDA clearances between them, and clearance programmes cost money. BrainKey has no clearance and no public record of raising what a submission programme needs. Its terms resolve that by defining the product as research and educational, which is coherent and cheaper.
6. Revenue looks like the working funding mechanism.One US practice publishes the retail split: “the cost is $950, which breaks down into the ProScan MRI ($500) and the BrainKey analysis of those images ($450).” At $450 an analysis, a few thousand scans a year would exceed every equity total any provider reports.

Commercial signals

What to watch

• A first Form D. Any priced round large enough to need one would end the vendor data disagreement in a single filing.
• A 510(k) submission, which would signal that the company intends to sell into clinical interpretation rather than wellness.
• Confirmation of the SimonMed relationship from SimonMed, and a name for the unnamed provider.
• Whether headcount tracks revenue. Twenty people on $350,000 of lifetime equity implies the business pays for itself.
• Any disclosure that reconciles the 7, 8 and 13 investor counts.

The BrainKey story on Healthcare DiscoveryHealthcare Discovery

Related companies

• XGenomes: Shared investor: Amino Capital. A Cambridge, Massachusetts company reading DNA in five letter words instead of one base at a time
• InVision Medical Technology: Shared investor: Amino Capital. Two FDA-cleared models that read heart ultrasounds already being performed, built by the lab that published the underlying papers first
• MediSearch: Shared investor: Amino Capital. A search engine that answers medical questions from published sources, built by two founders and backed by Y Combinator
• Brown Foods: Shared investor: Amino Capital. A Boston and India company growing bovine mammary cells in bioreactors to make whole cow milk, and now saying it has done the same with human milk

Sources

1. Public recordSEC EDGAR company and full text searches, zero resultsSEC · Sep 23, 2026
2. Public recordopenFDA 510(k), PMA and registration queries, no matchesFDA · Sep 23, 2026
3. Public recordopenFDA 510(k) records for Cortechs Labs, Icometrix and QuantibFDA · 2006 to 2026
4. Public recordPubMed affiliation search, 11 papers with a BrainKey affiliationNCBI · Sep 23, 2026
5. Provider dataBrain Key financials, 4 fundings, 7 investorsCB Insights · Sep 23, 2026
6. Provider dataBrainkey funding rounds, $150K, 8 investorsTracxn · Sep 23, 2026
7. Provider dataBrainkey profile, $350K raised, 13 investors, 14 employeesPitchBook · Sep 23, 2026
8. Provider dataBrain Key funding and investorsDealroom · Sep 23, 2026
9. IndependentStartup BrainKey offers brain MRI direct to consumersAuntMinnie · Oct 14, 2020
10. ClinicianA Closer Look at Your Brain Health, with the $950 retail splitPriority Physicians · 2026
11. DirectoryBrainKey page, Winter 2019 batch, team size 20Y Combinator · Sep 23, 2026
12. CompanyBrainKey and Microsoft Azure, naming an unidentified large US MRI providerMicrosoft for Startups Blog · Aug 26, 2025
13. CompanyBrainKey exhibitor profile naming SimonMed and whole body expansionDOC 2025 · 2025
14. CompanyBrainKey terms of service defining Brain Key, Inc. and the use limitsbrainkey.ai · Internet Archive, Nov 13, 2025
15. Founder bioOwen Phillips speaker biography naming YCombinator, Soma and Amino CapitalNeurotech Planet · 2021

Compiled from SEC, FDA, NIH, NSF and NCBI public records, commercial data providers and published reports as of September 23, 2026. No Regulation D notice exists for this company, so every capital figure on this page is vendor-reported or company-reported and is labeled accordingly. Healthcare Venture Capital Fund holds no position in BrainKey. This page is not an offer to sell or a recommendation to buy any security.